Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

1.260 -0.050 (-3.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease
Enveric's Akos Biosciences licensed its cannabinoid-COX-2 conjugate technology to Restoration Biologics for joint disease treatments, including osteoarthritis. 
Via Benzinga
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Closing of $5 Million Public Offering
From Enveric Biosciences, Inc.
Via Business Wire
What's going on in today's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Dow Edges Lower; Exxon Mobil Earnings Top Views
 
Via Benzinga
Topics Stocks
Which stocks are gapping on Friday?
The market is buzzing with gapping stocks on Friday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings
 
Via Benzinga
These stocks are moving in today's pre-market session
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Enveric Biosciences Announces Pricing of $5 Million Public Offering
From Enveric Biosciences, Inc.
Via Business Wire
What's going on in today's after hours session
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
From Enveric Biosciences
Via Business Wire
Let's take a look at the stocks that are in motion in today's session.
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Here are the top movers in Wednesday's session.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
From Enveric Biosciences
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results
 
Via Benzinga
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
From Enveric Biosciences, Inc.
Via Business Wire
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders
 
Via Benzinga
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal
Enveric licenses EB-002 to MycoMedica for neuropsychiatric treatment, focusing on EB-003's development with potential milestones up to $62M. 
Via Benzinga
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Announces Broad Range of Patent Issuances
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions
Enveric Biosciences expands its patent portfolio with five new U.S. patents, supporting treatments for depression, anxiety and epilepsy. 
Via Benzinga
Topics Intellectual Property
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.